Abstract

Circulating tumor cells (CTCs) are cells released from the primary and metastatic tumor and intravasate into the blood or lymphatic vessels, where they are transported to distant sites and act as seeds that initiate cancer metastases or the development of further lesions. Recent advances in CTC research have shown their relevance as prognostic markers for early and metastatic disease detection, predictive biomarkers for relapse, and response to medical intervention or therapy. The rapidly evolving landscape of CTC biology has opened new avenues for understanding cancer progression, metastasis, and treatment response. Additionally, translating these findings into clinical applications holds promise for improving cancer diagnostics, prognosis, and personalized therapeutic strategies. This review discusses the significance of CTCs in cancer research and their associated challenges. We explore recent developments in the detection and characterization of CTCs and their implications in cancer research and clinical practice.

MeSH

Neoplasm Metastasis, Therapeutics, Neoplasms, Research, Neoplastic Cells, Circulating

Cited by

• Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther, 2024
• Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer, 2024
• A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer. Front Immunol, 2025
• PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients. Cancer Res Commun, 2025
• Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review). Oncol Lett, 2024
• Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances. J Liq Biopsy, 2025